Insight, China's Pharmaceutical Industry

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

China’s National Healthcare Security Administration (NHSA) officially released the Version 3.0 Grouping Scheme for Diagnosis-Related...

Company Drug

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

Fineline Cube Sep 2, 2026

GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal...

Policy / Regulatory

NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors

Fineline Cube Sep 2, 2026

The National Medical Products Administration (NMPA) issued the Announcement on Further Strengthening the Management of...

Company Drug PIC

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate

Fineline Cube Sep 2, 2026

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that its SKINVIVE by Juvéderm, an injectable...

Company Drug

Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment

Fineline Cube Sep 2, 2026

Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Beijing Centergate Technologies (SHE: 000931), has received...

Company Drug

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

Fineline Cube Sep 2, 2026

Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1/-2 clinical trials of...

Company Drug

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

Fineline Cube Sep 2, 2026

CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced that SYS6010, its epidermal growth factor receptor...

Company Deals

Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates

Fineline Cube Sep 2, 2026

Huadong Medicine (SHE: 000963) announced that it signed a new additional collaboration agreement with its...

Company Deals

Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million

Fineline Cube Sep 2, 2026

Sino Biopharmaceutical (HKG: 1177) announced that its subsidiary, Chia Tai Tianqing (CTTQ), entered into an...

Company Drug

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Fineline Cube Sep 2, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its novel bispecific...

Company Deals PIC

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

Fineline Cube Sep 2, 2026

Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that...

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) issued the...

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026

China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Fineline Cube Sep 1, 2026

Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab,...

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Fineline Cube Sep 1, 2026

President Donald Trump announced new agreements with nine pharmaceutical companies to lower prescription drug prices...

Company Drug

Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million

Fineline Cube Sep 1, 2026

Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that it has initiated a Phase I...

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026

Johnson & Johnson MedTech and Jiangsu CED Medical Technology Co., Ltd. (“CED Medical”) have signed...

Company Drug

CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China

Fineline Cube Sep 1, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an...

Company Drug

Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China

Fineline Cube Sep 1, 2026

Ocumension Therapeutics (HKG: 1477) announced that OT-202, the company’s first-in-class candidate for the treatment of...

Company Deals

Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform

Fineline Cube Sep 1, 2026

Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of...

Insight, China's Pharmaceutical Industry

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate

Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates

Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China

Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China

Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform

You Missed

NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul

GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots

NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors

Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate